Skip to main content
AKBA logo

AKBA · Akebia Therapeutics, Inc. · Debt

Track AKBA — free
$0.42 +0.01 (+3.28%) At close · Nov 19 Play latest call Q3 2026 earnings call transcript
Market Cap
$117.26M
Shares
277.66M
Volume · Nov 19 2.75M Avg daily vol (3M) 8.17M

Debt Profile

Completed filing coverage through Jan 30, 2026

Reported borrowing balances, repayment dates and agreement terms, with links to the underlying filings.

Read debt and covenant terms in your AI or your code through MCP and the API →

Reported debt balances

Each amount keeps its reported scope. Related balance-sheet measures appear under the borrowing they describe.

Reported balanceAs ofAmountSource
Long-term debt, including current maturities 2026-09-30 USD 50,270,000 10-Q filed 2026-11-05
Related accounting measures — not additional borrowing

Carrying amounts can reflect issuance costs or discounts. Differences between these measures are not necessarily repayments due within a year.

Current portion of long-term debt
USD 37,493,000
Noncurrent debt carrying amount
USD 12,777,000
Operating lease liabilities 2026-09-30 USD 10,220,000 10-Q filed 2026-11-05
Related accounting measures — not additional borrowing

Carrying amounts can reflect issuance costs or discounts. Differences between these measures are not necessarily repayments due within a year.

Current operating lease liabilities
USD 930,000
Noncurrent operating lease liabilities
USD 9,291,000
Instrument and agreement coverage is incomplete. Additional filings are awaiting review.

Covenants

Covenant terms have not yet been verified for this profile.

The balance figures do not establish whether covenants apply or whether the company complies with them.

Loans, facilities and notes

The instrument breakdown is not yet verified. Read the debt note in the linked report for borrowing terms and maturity conditions.

Key facts CIK 1517022 CUSIP 00972D105 13F (30d) 157 filings 140 filers Visit website Investor relations